XSHE
002317
Market cap2.94bUSD
Oct 09, Last price
25.49CNY
1D
10.01%
1Q
-13.71%
Jan 2017
106.40%
IPO
169.67%
Name
Guangdong Zhongsheng Pharmaceutical Co Ltd
Chart & performance
P/E
78.57
P/S
8.59
EPS
0.32
Div yield, %
0.86%
Shrs. gr., 5y
0.79%
Rev. gr., 5y
5.88%
Revenues
2.52b
+2.24%
Net income
276m
P
CFO
305m
-9.66%
Dividend
May 29, 20260.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.
Key people
Xiaoxin Chen
Vice President · since 2025
Shuang Liu
Vice President · since 2018
Chunhua Long
Chief Financial Officer, Vice President, Director · since 2014
Rikang Luo
Vice President · since 2024
Wei Yang
Secretary of the Board · since 2023
Yonghong Chen
Chairman of the Board, President · since 2023
Hougan Huang
Staff Elected Director · since 2025
Peng'an Shan
Director · since 2016
Wen Tan
Director · since 2019
Luman Wang
Director · since 2025
Yuchong Zhang
Vice Chairman of the Board, Senior Vice President · since 2020
Baoguo Jiang
Independent Director · since 2025
Ruichao Lin
Independent Director · since 2019
Yunguo Liu
Independent Director · since 2025
Independent Director · since 2025
Headquarters & legal address
广东省东莞市石龙镇西湖工业区信息产业园
东莞市, GD 100000
CN
东莞市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||